FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980970087> ?p ?o ?g. }

• W2980970087 endingPage "894.e18" @default.
• W2980970087 startingPage "894.e11" @default.
• W2980970087 abstract "The diagnosis of prostate cancer has changed. Improved magnetic resonance imaging (MRI) technology with diffusion-weighted imaging has led to the use of multiparametric MRI (mpMRI) before biopsy in patients suspected of having prostate cancer. This has the advantage that patients with a negative mpMRI may not need biopsy, therefore avoiding the risk of complications. Those in whom mpMRI is positive can have targeted biopsies with a higher probability of diagnosing clinically significant cancer. Prostate Cancer UK (PCUK) and the British Society of Urogenital Radiology submitted a Freedom of Information (FOI) request in 2016 to UK health areas in order to assess the use of mpMRI before biopsy as part of the initial diagnosis pathway. Another request was submitted by PCUK in 2018 to assess the progress made in the UK between these two dates. Both requests had the secondary aim of identifying barriers to the implementation of mpMRI. The FOI requests showed an increase in the use of mpMRI before biopsy with 59% of areas reporting improvement between the two requests. There has been a reduction in the percentage of areas not providing any form of pre-biopsy MRI from 25% in 2016 to 13% in 2018. There remains, however, geographical variation in implementation across the UK nations. Imaging practice also shows variation with some areas performing scans without dynamic contrast enhancement (DCE) and using the findings to guide referral decisions for biopsy. Eligibility criteria for pre-biopsy MRI also vary leading to some restrictive practices. Reported barriers to implementation included scanner capacity and staffing levels. Recent guidelines and recommendations by the National Institute for Health and Care Excellence (NICE) and NHS England for men aged 50–69 years with a prostate-specific antigen (PSA) level between >3 and <30 ng/ml to receive mpMRI before biopsy put further pressure on already understaffed and under-resourced radiology departments. The diagnosis of prostate cancer has changed. Improved magnetic resonance imaging (MRI) technology with diffusion-weighted imaging has led to the use of multiparametric MRI (mpMRI) before biopsy in patients suspected of having prostate cancer. This has the advantage that patients with a negative mpMRI may not need biopsy, therefore avoiding the risk of complications. Those in whom mpMRI is positive can have targeted biopsies with a higher probability of diagnosing clinically significant cancer. Prostate Cancer UK (PCUK) and the British Society of Urogenital Radiology submitted a Freedom of Information (FOI) request in 2016 to UK health areas in order to assess the use of mpMRI before biopsy as part of the initial diagnosis pathway. Another request was submitted by PCUK in 2018 to assess the progress made in the UK between these two dates. Both requests had the secondary aim of identifying barriers to the implementation of mpMRI. The FOI requests showed an increase in the use of mpMRI before biopsy with 59% of areas reporting improvement between the two requests. There has been a reduction in the percentage of areas not providing any form of pre-biopsy MRI from 25% in 2016 to 13% in 2018. There remains, however, geographical variation in implementation across the UK nations. Imaging practice also shows variation with some areas performing scans without dynamic contrast enhancement (DCE) and using the findings to guide referral decisions for biopsy. Eligibility criteria for pre-biopsy MRI also vary leading to some restrictive practices. Reported barriers to implementation included scanner capacity and staffing levels. Recent guidelines and recommendations by the National Institute for Health and Care Excellence (NICE) and NHS England for men aged 50–69 years with a prostate-specific antigen (PSA) level between >3 and <30 ng/ml to receive mpMRI before biopsy put further pressure on already understaffed and under-resourced radiology departments." @default.
• W2980970087 created "2019-10-25" @default.
• W2980970087 creator A5002788543 @default.
• W2980970087 creator A5003109533 @default.
• W2980970087 creator A5042451343 @default.
• W2980970087 creator A5064101088 @default.
• W2980970087 date "2019-11-01" @default.
• W2980970087 modified "2023-10-18" @default.
• W2980970087 title "Prostate mpMRI in the UK: the state of the nation" @default.
• W2980970087 cites W2070348309 @default.
• W2980970087 cites W2082328647 @default.
• W2980970087 cites W2084530435 @default.
• W2980970087 cites W2115895082 @default.
• W2980970087 cites W2143884385 @default.
• W2980970087 cites W2156992415 @default.
• W2980970087 cites W2577453388 @default.
• W2980970087 cites W2793905111 @default.
• W2980970087 cites W2801556653 @default.
• W2980970087 cites W2884979218 @default.
• W2980970087 cites W2900548778 @default.
• W2980970087 cites W2922071185 @default.
• W2980970087 cites W4250966750 @default.
• W2980970087 doi "https://doi.org/10.1016/j.crad.2019.09.129" @default.
• W2980970087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31627803" @default.
• W2980970087 hasPublicationYear "2019" @default.
• W2980970087 type Work @default.
• W2980970087 sameAs 2980970087 @default.
• W2980970087 citedByCount "20" @default.
• W2980970087 countsByYear W29809700872019 @default.
• W2980970087 countsByYear W29809700872020 @default.
• W2980970087 countsByYear W29809700872021 @default.
• W2980970087 countsByYear W29809700872022 @default.
• W2980970087 countsByYear W29809700872023 @default.
• W2980970087 crossrefType "journal-article" @default.
• W2980970087 hasAuthorship W2980970087A5002788543 @default.
• W2980970087 hasAuthorship W2980970087A5003109533 @default.
• W2980970087 hasAuthorship W2980970087A5042451343 @default.
• W2980970087 hasAuthorship W2980970087A5064101088 @default.
• W2980970087 hasConcept C121608353 @default.
• W2980970087 hasConcept C126322002 @default.
• W2980970087 hasConcept C126838900 @default.
• W2980970087 hasConcept C143409427 @default.
• W2980970087 hasConcept C159110408 @default.
• W2980970087 hasConcept C19527891 @default.
• W2980970087 hasConcept C2775934546 @default.
• W2980970087 hasConcept C2776135927 @default.
• W2980970087 hasConcept C2776235491 @default.
• W2980970087 hasConcept C2777512617 @default.
• W2980970087 hasConcept C2780192828 @default.
• W2980970087 hasConcept C2781217009 @default.
• W2980970087 hasConcept C512399662 @default.
• W2980970087 hasConcept C71924100 @default.
• W2980970087 hasConceptScore W2980970087C121608353 @default.
• W2980970087 hasConceptScore W2980970087C126322002 @default.
• W2980970087 hasConceptScore W2980970087C126838900 @default.
• W2980970087 hasConceptScore W2980970087C143409427 @default.
• W2980970087 hasConceptScore W2980970087C159110408 @default.
• W2980970087 hasConceptScore W2980970087C19527891 @default.
• W2980970087 hasConceptScore W2980970087C2775934546 @default.
• W2980970087 hasConceptScore W2980970087C2776135927 @default.
• W2980970087 hasConceptScore W2980970087C2776235491 @default.
• W2980970087 hasConceptScore W2980970087C2777512617 @default.
• W2980970087 hasConceptScore W2980970087C2780192828 @default.
• W2980970087 hasConceptScore W2980970087C2781217009 @default.
• W2980970087 hasConceptScore W2980970087C512399662 @default.
• W2980970087 hasConceptScore W2980970087C71924100 @default.
• W2980970087 hasIssue "11" @default.
• W2980970087 hasLocation W29809700871 @default.
• W2980970087 hasLocation W29809700872 @default.
• W2980970087 hasOpenAccess W2980970087 @default.
• W2980970087 hasPrimaryLocation W29809700871 @default.
• W2980970087 hasRelatedWork W1551416944 @default.
• W2980970087 hasRelatedWork W1725314107 @default.
• W2980970087 hasRelatedWork W1884231116 @default.
• W2980970087 hasRelatedWork W2168798245 @default.
• W2980970087 hasRelatedWork W2394564140 @default.
• W2980970087 hasRelatedWork W2409990396 @default.
• W2980970087 hasRelatedWork W2410191098 @default.
• W2980970087 hasRelatedWork W2566665866 @default.
• W2980970087 hasRelatedWork W2785380349 @default.
• W2980970087 hasRelatedWork W3197418554 @default.
• W2980970087 hasVolume "74" @default.
• W2980970087 isParatext "false" @default.
• W2980970087 isRetracted "false" @default.
• W2980970087 magId "2980970087" @default.
• W2980970087 workType "article" @default.